Physician profile
John Valentine
NPI 1144263419
$8,948.78
in general payments reported to CMS, 2019-2025
20 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $7,519 · 2021: $122 · 2022: $222 · 2023: $215 · 2024: $229 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519 · Education: $79.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.16 |
| Education | $79.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,000.00 | 2020 | |
| Celgene Corporation | $2,546.63 | 2020-2022 | |
| Abbvie INC. | $419.95 | 2019-2024 | Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $322.74 | 2019-2024 | Entyvio |
| Allergan, INC. | $165.03 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Genentech USA, INC. | $125.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $91.76 | 2021 | |
| Samsung Hme America, INC. | $50.00 | 2023 | |
| Janssen Biotech, INC. | $48.95 | 2023 | Tremfya, Stelara |
| Pfizer INC. | $31.00 | 2025 | |
| Genentech, INC. | $22.72 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Valentine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.